Neurological Complications during Treatment of Middle East Respiratory Syndrome
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background and Purpose Middle East respiratory syndrome (MERS) has a high mortality rate and pandemic potential. However, the neurological manifestations of MERS have rarely been reported since it first emerged in 2012. Methods We evaluated four patients with laboratory-confirmed MERS coronavirus (CoV) infections who showed neurological complications during MERS treatment. These 4 patients were from a cohort of 23 patients who were treated at a single designated hospital during the 2015 outbreak in the Republic of Korea. The clinical presentations, laboratory findings, and prognoses are described. Results Four of the 23 admitted MERS patients reported neurological symptoms during or after MERS-CoV treatment. The potential diagnoses in these four cases included Bickerstaff’s encephalitis overlapping with Guillain-Barré syndrome, intensive-care-unit-acquired weakness, or other toxic or infectious neuropathies. Neurological complications did not appear concomitantly with respiratory symptoms, instead being delayed by 2–3 weeks. Conclusions Neuromuscular complications are not rare during MERS treatment, and they may have previously been underdiagnosed. Understanding the neurological manifestations is important in an infectious disease such as MERS, because these symptoms are rarely evaluated thoroughly during treatment, and they may interfere with the prognosis or require treatment modification.
Abstract
Background and Purpose Middle East respiratory syndrome (MERS) has a high mortality rate and pandemic potential. However, the neurological manifestations of MERS have rarely been reported since it first emerged in 2012. Methods We evaluated four patients with laboratory-confirmed MERS coronavirus (CoV) infections who showed neurological complications during MERS treatment. These 4 patients were from a cohort of 23 patients who were treated at a single designated hospital during the 2015 outbreak in the Republic of Korea. The clinical presentations, laboratory findings, and prognoses are described. Results Four of the 23 admitted MERS patients reported neurological symptoms during or after MERS-CoV treatment. The potential diagnoses in these four cases included Bickerstaff’s encephalitis overlapping with Guillain-Barré syndrome, intensive-care-unit-acquired weakness, or other toxic or infectious neuropathies. Neurological complications did not appear concomitantly with respiratory symptoms, instead being delayed by 2–3 weeks. Conclusions Neuromuscular complications are not rare during MERS treatment, and they may have previously been underdiagnosed. Understanding the neurological manifestations is important in an infectious disease such as MERS, because these symptoms are rarely evaluated thoroughly during treatment, and they may interfere with the prognosis or require treatment modification.
참고문헌 (30)
- "Middle East Respiratory Syndrome Coronavirus Infections-Disease Outbreak News"[URL]
- Zaki AM, "Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia", N Engl J Med, 367, pp.1814~1820 (2012)
- "Summary of MERS Statistics in the Republic of Korea"[URL]
- WHO Mers-Cov Research Group, "State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans", PLoS Curr, 5 (2013)
- Desforges M, "Human coronaviruses: viral and cellular factors involved in neuroinvasiveness and neuropathogenesis", Virus Res, 194, pp.145~158 (2014)
- Saad M, "Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia", Int J Infect Dis, 29, pp.301~306 (2014)
- Arabi YM, "Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV)", Infection, 43, pp.495~501 (2015)
- Algahtani H, "Neurological complications of Middle East respiratory syndrome coronavirus: a report of two cases and review of the literature", Case Rep Neurol Med, 2016, pp.3502683~ (2016)
- "Technical Guidance on Laboratory: Middle East respiratory syndrome coronavirus"[URL]
- Singer M, "The third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)", JAMA, 315, pp.801~810 (2016)
- Fine MJ, "A prediction rule to identify low-risk patients with communityacquired pneumonia", N Engl J Med, 336, pp.243~250 (1997)
- Le Gall JR, "A new Simplified Acute Physiology Score (SAPS II) based on a European", North American multicenter study, 1993, pp.270, 2957~2963
- 정용필, "Antiviral Treatment Guidelines for Middle East Respiratory Syndrome", Infection and Chemotherapy, 47(3), pp.212~222 (2015), 대한감염학회
- Wakerley BR, "Guillain-Barré and Miller Fisher syndromes--new diagnostic classification", Nat Rev Neurol, 10, pp.537~544 (2014)
- Mori M, "Clinical features and prognosis of Miller Fisher syndrome", Neurology, 56, pp.1104~1106 (2001)
- Shahrizaila N, "Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome", J Neurol Neurosurg Psychiatry, 84, pp.576~583 (2013)
- Galvin R, "EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy", Eur J Neurol, 17, pp.1408~1418 (2010)
- Wakerley BR, "Mimics and chameleons in Guillain-Barré and Miller Fisher syndromes", Pract Neurol, 15, pp.90~99 (2015)
- Dhand UK, "Clinical approach to the weak patient in the intensive care unit", Respir Care, 51, pp.1024~1040 (2006)
- Latronico N, "Critical illness polyneuropathy and myopathy:a major cause of muscle weakness and paralysis", Lancet Neurol, 10, pp.931~941 (2011)
- van den Berg B, "Paraparetic Guillain-Barré syndrome", Neurology, 82, pp.1984~1989 (2014)
- Briani C, "Peripheral neurotoxicity of pegylated interferon alpha: a prospective study in patients with HCV", Neurology, 67, pp.781~785 (2006)
- Meriggioli MN, "Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-alpha", Muscle Nerve, 23, pp.433~435 (2000)
- Khiani V, "Acute inflammatory demyelinating polyneuropathy associated with pegylated interferon alpha 2a therapy for chronic hepatitis C virus infection", World J Gastroenterol, 14, pp.318~321 (2008)
- Ellis RJ, "Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy", Ann Neurol, 64, pp.566~572 (2008)
- Zumla A, "Middle East respiratory syndrome", Lancet, 386, pp.995~1007 (2015)
- Arbour N, "Neuroinvasion by human respiratory coronaviruses", J Virol, 74, pp.8913~8921 (2000)
- Chan JF, "Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC", 2012: implications for disease pathogenesis and clinical manifestation, 2013, pp.207, 1743~1752
- Tsai LK, "Neuromuscular disorders in severe acute respiratory syndrome", Arch Neurol, 61, pp.1669~1673 (2004)
- Umapathi T, "Large artery ischaemic stroke in severe acute respiratory syndrome (SARS)", J Neurol, 251, pp.1227~1231 (2004)